Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography

Janie M. Lee, Linn Abraham, Diana L. Lam, Diana S.M. Buist, Karla Kerlikowske, Diana L Miglioretti, Nehmat Houssami, Constance D. Lehman, Louise M. Henderson, Rebecca A. Hubbard

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose The aim of the current study was to characterize the risk of interval invasive second breast cancers within 5 years of primary breast cancer treatment. Methods We examined 65,084 surveillance mammograms from 18,366 women with a primary breast cancer diagnosis of unilateral ductal carcinoma in situ or stage I to III invasive breast carcinoma performed from 1996 to 2012 in the Breast Cancer Surveillance Consortium. Interval invasive breast cancer was defined as ipsilateral or contralateral cancer diagnosed within 1 year after a negative surveillance mammogram. Discrete-time survival models—adjusted for all covariates—were used to estimate the probability of interval invasive cancer, given the risk factors for each surveillance round, and aggregated across rounds to estimate the 5-year cumulative probability of interval invasive cancer. Results We observed 474 surveillance-detected cancers—334 invasive and 140 ductal carcinoma in situ—and 186 interval invasive cancers which yielded a cancer detection rate of 7.3 per 1,000 examinations (95% CI, 6.6 to 8.0) and an interval invasive cancer rate of 2.9 per 1,000 examinations (95% CI, 2.5 to 3.3). Median cumulative 5-year interval cancer risk was 1.4% (interquartile range, 0.8% to 2.3%; 10th to 90th percentile range, 0.5% to 3.7%), and 15% of women had $ 3% 5-year interval invasive cancer risk. Cumulative 5-year interval cancer risk was highest for women with estrogen receptor– and progesterone receptor–negative primary breast cancer (2.6%; 95% CI, 1.7% to 3.5%), interval cancer presentation at primary diagnosis (2.2%; 95% CI, 1.5% to 2.9%), and breast conservation without radiation (1.8%; 95% CI, 1.1% to 2.4%). Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance.

Original languageEnglish (US)
Pages (from-to)2070-2077
Number of pages8
JournalJournal of Clinical Oncology
Volume36
Issue number20
DOIs
StatePublished - Jul 10 2018

Fingerprint

Second Primary Neoplasms
Mammography
Breast Neoplasms
Neoplasms
Ductal Carcinoma
Carcinoma, Intraductal, Noninfiltrating
Estrogen Receptors
Progesterone
Breast
Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography. / Lee, Janie M.; Abraham, Linn; Lam, Diana L.; Buist, Diana S.M.; Kerlikowske, Karla; Miglioretti, Diana L; Houssami, Nehmat; Lehman, Constance D.; Henderson, Louise M.; Hubbard, Rebecca A.

In: Journal of Clinical Oncology, Vol. 36, No. 20, 10.07.2018, p. 2070-2077.

Research output: Contribution to journalArticle

Lee, JM, Abraham, L, Lam, DL, Buist, DSM, Kerlikowske, K, Miglioretti, DL, Houssami, N, Lehman, CD, Henderson, LM & Hubbard, RA 2018, 'Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography', Journal of Clinical Oncology, vol. 36, no. 20, pp. 2070-2077. https://doi.org/10.1200/JCO.2017.76.8267
Lee, Janie M. ; Abraham, Linn ; Lam, Diana L. ; Buist, Diana S.M. ; Kerlikowske, Karla ; Miglioretti, Diana L ; Houssami, Nehmat ; Lehman, Constance D. ; Henderson, Louise M. ; Hubbard, Rebecca A. / Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 20. pp. 2070-2077.
@article{10eb6a332d4c427886347eaed196ef4e,
title = "Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography",
abstract = "Purpose The aim of the current study was to characterize the risk of interval invasive second breast cancers within 5 years of primary breast cancer treatment. Methods We examined 65,084 surveillance mammograms from 18,366 women with a primary breast cancer diagnosis of unilateral ductal carcinoma in situ or stage I to III invasive breast carcinoma performed from 1996 to 2012 in the Breast Cancer Surveillance Consortium. Interval invasive breast cancer was defined as ipsilateral or contralateral cancer diagnosed within 1 year after a negative surveillance mammogram. Discrete-time survival models—adjusted for all covariates—were used to estimate the probability of interval invasive cancer, given the risk factors for each surveillance round, and aggregated across rounds to estimate the 5-year cumulative probability of interval invasive cancer. Results We observed 474 surveillance-detected cancers—334 invasive and 140 ductal carcinoma in situ—and 186 interval invasive cancers which yielded a cancer detection rate of 7.3 per 1,000 examinations (95{\%} CI, 6.6 to 8.0) and an interval invasive cancer rate of 2.9 per 1,000 examinations (95{\%} CI, 2.5 to 3.3). Median cumulative 5-year interval cancer risk was 1.4{\%} (interquartile range, 0.8{\%} to 2.3{\%}; 10th to 90th percentile range, 0.5{\%} to 3.7{\%}), and 15{\%} of women had $ 3{\%} 5-year interval invasive cancer risk. Cumulative 5-year interval cancer risk was highest for women with estrogen receptor– and progesterone receptor–negative primary breast cancer (2.6{\%}; 95{\%} CI, 1.7{\%} to 3.5{\%}), interval cancer presentation at primary diagnosis (2.2{\%}; 95{\%} CI, 1.5{\%} to 2.9{\%}), and breast conservation without radiation (1.8{\%}; 95{\%} CI, 1.1{\%} to 2.4{\%}). Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance.",
author = "Lee, {Janie M.} and Linn Abraham and Lam, {Diana L.} and Buist, {Diana S.M.} and Karla Kerlikowske and Miglioretti, {Diana L} and Nehmat Houssami and Lehman, {Constance D.} and Henderson, {Louise M.} and Hubbard, {Rebecca A.}",
year = "2018",
month = "7",
day = "10",
doi = "10.1200/JCO.2017.76.8267",
language = "English (US)",
volume = "36",
pages = "2070--2077",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography

AU - Lee, Janie M.

AU - Abraham, Linn

AU - Lam, Diana L.

AU - Buist, Diana S.M.

AU - Kerlikowske, Karla

AU - Miglioretti, Diana L

AU - Houssami, Nehmat

AU - Lehman, Constance D.

AU - Henderson, Louise M.

AU - Hubbard, Rebecca A.

PY - 2018/7/10

Y1 - 2018/7/10

N2 - Purpose The aim of the current study was to characterize the risk of interval invasive second breast cancers within 5 years of primary breast cancer treatment. Methods We examined 65,084 surveillance mammograms from 18,366 women with a primary breast cancer diagnosis of unilateral ductal carcinoma in situ or stage I to III invasive breast carcinoma performed from 1996 to 2012 in the Breast Cancer Surveillance Consortium. Interval invasive breast cancer was defined as ipsilateral or contralateral cancer diagnosed within 1 year after a negative surveillance mammogram. Discrete-time survival models—adjusted for all covariates—were used to estimate the probability of interval invasive cancer, given the risk factors for each surveillance round, and aggregated across rounds to estimate the 5-year cumulative probability of interval invasive cancer. Results We observed 474 surveillance-detected cancers—334 invasive and 140 ductal carcinoma in situ—and 186 interval invasive cancers which yielded a cancer detection rate of 7.3 per 1,000 examinations (95% CI, 6.6 to 8.0) and an interval invasive cancer rate of 2.9 per 1,000 examinations (95% CI, 2.5 to 3.3). Median cumulative 5-year interval cancer risk was 1.4% (interquartile range, 0.8% to 2.3%; 10th to 90th percentile range, 0.5% to 3.7%), and 15% of women had $ 3% 5-year interval invasive cancer risk. Cumulative 5-year interval cancer risk was highest for women with estrogen receptor– and progesterone receptor–negative primary breast cancer (2.6%; 95% CI, 1.7% to 3.5%), interval cancer presentation at primary diagnosis (2.2%; 95% CI, 1.5% to 2.9%), and breast conservation without radiation (1.8%; 95% CI, 1.1% to 2.4%). Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance.

AB - Purpose The aim of the current study was to characterize the risk of interval invasive second breast cancers within 5 years of primary breast cancer treatment. Methods We examined 65,084 surveillance mammograms from 18,366 women with a primary breast cancer diagnosis of unilateral ductal carcinoma in situ or stage I to III invasive breast carcinoma performed from 1996 to 2012 in the Breast Cancer Surveillance Consortium. Interval invasive breast cancer was defined as ipsilateral or contralateral cancer diagnosed within 1 year after a negative surveillance mammogram. Discrete-time survival models—adjusted for all covariates—were used to estimate the probability of interval invasive cancer, given the risk factors for each surveillance round, and aggregated across rounds to estimate the 5-year cumulative probability of interval invasive cancer. Results We observed 474 surveillance-detected cancers—334 invasive and 140 ductal carcinoma in situ—and 186 interval invasive cancers which yielded a cancer detection rate of 7.3 per 1,000 examinations (95% CI, 6.6 to 8.0) and an interval invasive cancer rate of 2.9 per 1,000 examinations (95% CI, 2.5 to 3.3). Median cumulative 5-year interval cancer risk was 1.4% (interquartile range, 0.8% to 2.3%; 10th to 90th percentile range, 0.5% to 3.7%), and 15% of women had $ 3% 5-year interval invasive cancer risk. Cumulative 5-year interval cancer risk was highest for women with estrogen receptor– and progesterone receptor–negative primary breast cancer (2.6%; 95% CI, 1.7% to 3.5%), interval cancer presentation at primary diagnosis (2.2%; 95% CI, 1.5% to 2.9%), and breast conservation without radiation (1.8%; 95% CI, 1.1% to 2.4%). Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance.

UR - http://www.scopus.com/inward/record.url?scp=85049583158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049583158&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.76.8267

DO - 10.1200/JCO.2017.76.8267

M3 - Article

C2 - 29718790

AN - SCOPUS:85049583158

VL - 36

SP - 2070

EP - 2077

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -